Print

Ellinghorst IR compiles independent consensus forecasts of UCB based on the financial estimates of various analysts covering UCB.

In order to provide meaningful data only regularly updated or reiterated estimates are included in the consensus. The tables below are based on the estimates of almost 20 different brokers. See the list of analysts and their contact details here

If you wish to be informed whenever we have updated consensus, simply send an e-mail to This email address is being protected from spambots. You need JavaScript enabled to view it. quoting "consensus email alert" as subject.  

 ucb

UCB HY 2021 Consensus Estimates 

In € million HY 2020a

HY 2021e

Average

HY 2021e

Median

Product Sales Consensus       
Cimzia 842 864 864
Vimpat 722 746 750
Keppra  419 398 386
Briviact 144 167 166
Neupro 156 144 145
Evenity*   n/a n/a
Nayzilam 11  23 21
P&L Consensus       
Net Sales 2,491 2,556 2,546
Revenue 2,608 2,669 2,660
Adj. EBIT 614 604 610
Adj. EBITDA 783 784 791
Net Profit (attr. to UCB shareh.) 363 495 459
Core EPS (€) 2.77 2.85 2.85

 *not enough analysts forecast for HY global Evenity available  

UCB FY Consensus Product Sales Estimates (Average)

In € million 2020a 2021e 2022e 2023e  2024e  2025e  2026e Peak Sales NPV
Core Products                  
Cimzia 1,799 1,874 1,938 1,957 1,832 1,575 1,346   5,239
Vimpat 1,451 1,537 928 634 541 486 438   2,102
Keppra  788 761 680 626 578 538 498   2,308
Briviact 288 349 420 486 544 599 550 620 1,931
Neupro 311 285 248 214 182 157 138   541
New Products
(global sales, non-risk adj.)
                 
Evenity    488 653 797 923 1,030 1,119 1,253 2,221
Nayzilam 26  52 75 96 116 130 134 161 416
Potential new Product Launches
(global sales, non-risk adj.)
                 
Bimekizumab   66 308 638 998 1,385 1,730 2,625 7,193
Zilucoplan   1 27 128 297 426 611 1,158 2,088
Rozanolixizumab    0 23 77 190 313 459 905 1,416
Dapimab   0 0 1 7 26 111    
Staccato alprazolam   0 0 7 25 75 119 272  
Bepranemab   0 0 7 40 121 212    

 

UCB FY Consensus Earnings Estimates (Average)

In € million 2020a 2021e 2022e 2023e  2024e 2025e
Net Sales 5,052   5,289  4,993  5,163 5,520  5,826 
Revenue 5,347   5,543 5,236  5,399  5,749  6,054 
Adjusted EBIT 1,093   1,176 1,106  1,225  1,441   1,619
Adjusted EBITDA 1,441   1,540 1,457  1,592  1,816  1,992 
Net Profit*  732  888  839  946  1,135  1,291 
Core EPS (€) 5.36  5.69 5.32 5.92 6.93  7.76 

*attributable to UCB shareholders  

UCB FY Consensus Product Sales Estimates (Median)

In € million 2020a 2021e 2022e 2023e  2024e  2025e  2026e Peak Sales NPV
Core Products                  
Cimzia 1,799 1,870 1,938 1,952 1,837 1,554 1,319   5,126
Vimpat 1,451 1,536 929 633 545 483 400   2,357
Keppra  788 747 677 619 571 531 485   2,039
Briviact 288 346 418 484 548 590 565 613 1,693
Neupro 311 290 246 203 171 157 141   529
New Products
(global sales, non-risk adj.)
                 
Evenity    495 670 823 961 1,076 1,151 1,165 2,323
Nayzilam 26  49 70 90 116 130 134 150 428
Potential new Product Launches
(global sales, non-risk adj.)
                 
Bimekizumab   42 293 669 1,003 1,372 1,736 2,501 5,842
Zilucoplan   0 0 121 283 454 591 1,192 2,115
Rozanolixizumab    0 0 67 156 299 480 888 1,144
Dapimab   0 0 0 0 29 70    
Staccato alprazolam   0 0 0 23 75 94 255  
Bepranemab   0 0 0 26 101 184    

 

UCB FY Consensus Earnings Estimates (Median)

In € million 2020a 2021e 2022e 2023e  2024e 2025e
Net Sales 5,052  5,298  4,969  5,174  5,580   5,805
Revenue 5,347  5,561  5,212   5,411 5,811  6,057 
Adjusted EBIT 1,093  1,176  1,138  1,227  1,473  1,646 
Adjusted EBITDA 1,441  1,548 1,454  1,623  1,824   2,003
Net Profit*  732  895  842  950  1,109 1,287
Core EPS (€) 5.36  5.69 5.32  5.90  6.94  7.78 

*attributable to UCB shareholders

Downloads:
UCB HY 2021 & FY Consensus (Excel)
UCB FY P&L Consensus (PDF)
UCB FY Product Sales Consensus (PDF)
UCB HY 2021 Consensus (PDF)

Last updated 15 July 2021



Check out UCB's new IR Apps: 

App Apple Store

App Google Play

 

Disclaimer:

This document has been compiled by Ellinghorst IR Ltd. for information purposes only and is not intended to constitute investment advice. It is based on estimates and forecasts of various analysts regarding revenues, earnings and business developments of the relevant company. Such estimates and forecasts cannot be independently verified by reason of the subjective character. Ellinghorst IR Ltd. gives no guarantee, representation or warranty and is not responsible or liable as to its accuracy and completeness. Ellinghorst IR Ltd. has not commented and will not comment on any of the individual financial forecasts used to generate the information contained herein.